chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Debilitating headache; Chills; Fever; Lymph node swelling in affected arm pit; Nausea; This is a spontaneous report received from a contactable reporter(s) (Other HCP). The reporter is the patient. A 58-year-old female patient (not pregnant) received bnt162b2 (BNT162B2), administered in arm left, administration date 11Sep2021 09:00 (Lot number: FE3592) at the age of 58 years as dose 3 (booster), single for covid-19 immunisation. Relevant medical history included: "High Blood Pressure" (unspecified if ongoing), notes: High Blood Pressure. Concomitant medication(s) included: FLU, administration date 08Sep2021; LOSARTAN; HYDROCHLOROTHIAZIDE. Vaccination history included: Bnt162b2 (Dose Number: 1, Batch/Lot No: EH9899, Location of injection: Arm Right, Vaccine Administration Time: 05:00 PM), administration date: 16Dec2020, when the patient was 58 years old, for Covid-19 immunization; Bnt162b2 (Dose Number: 2, Batch/Lot No: EK9231, Location of injection: Arm Right, Vaccine Administration Time: 04:30 PM), administration date: 05Jan2021, when the patient was 58 years old, for Covid-19 immunization. The following information was reported: HEADACHE (non-serious) with onset 11Sep2021 22:00, outcome "recovered" (2021), described as "Debilitating headache"; CHILLS (non-serious) with onset 11Sep2021 22:00, outcome "recovered" (2021), described as "Chills"; PYREXIA (non-serious) with onset 11Sep2021 22:00, outcome "recovered" (2021), described as "Fever"; LYMPHADENOPATHY (non-serious) with onset 11Sep2021 22:00, outcome "recovered" (2021), described as "Lymph node swelling in affected arm pit"; NAUSEA (non-serious) with onset 11Sep2021 22:00, outcome "recovered" (2021), described as "Nausea". Therapeutic measures were not taken as a result of headache, chills, pyrexia, lymphadenopathy, nausea. Additional information The patient received other vaccine in four weeks was FLU SHOT GLAXOSMITHKLINE, lot number 5AJ3B, dose number 1 and vaccine location was Left Arm. The other medications the patient received within 2 weeks of vaccination: Losartan, Hydrochlorothiazide. Worse than previous two covid shots. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient has not been tested for COVID-19. The patient did not have any Known allergies   No follow-up attempts are possible. No further information is expected.
Really bad body aches, fever, sore throat, nausea, arm sore swollen and warm to the touch
Severe chronic sinusitis causing left & right nasal inflammation with internal lesions present.  Methods to treat symptoms include nasal washing, Allegra-D 12 hrs and prednisone as needed for inflammation.   Symptoms have persisted since start date 5/20/2021.  Vaccine received from Hospital.  Currently under allergy clinic & Dr. MD medical care for resolution.
pt recvd vax 10AM 17DEC93 & sz started 9PM the same day on 17DEC93 w/o fever; no locals swelling;
Treatment of COVID-19; Treatment of COVID-19; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 69-year-old female patient (not pregnant) received BNT162b2 (BNT162B2), in Aug2022 as dose 5 (booster), single (Batch/Lot number: unknown) at the age of 69 years, in left arm for covid-19 immunisation; coviD-19 vaccine (COVID-19 VACCINE), as dose 1, single (Batch/Lot number: unknown), as dose 2, single (Batch/Lot number: unknown), as dose 3 (booster), single (Batch/Lot number: unknown) and as dose 4 (booster), single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history included: "asthma" (unspecified if ongoing); "HBP" (unspecified if ongoing). The patient's concomitant medications were not reported. Past drug history included: Compazine, reaction(s): "Known allergies: compazine". The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant), outcome "unknown" and all described as "Treatment of COVID-19". Therapeutic measures were taken as a result of drug ineffective, covid-19.  The information on the batch/lot number for BNT162b2 has been requested and will be submitted if and when received.
This spontaneous case reported by a consumer, describes the occurrence of lethargy (feeling lethargic), myalgia (achiness) and fatigue (mild to moderate fatigue) in a 62-year-old female patient who received mRNA-1273 (Moderna COVID-19 vaccine, batch# 012L20A) for COVID-19 immunization. The patient's past medical history included no adverse event. On Jan 13, 2021, patient received dose of mRNA-1273 (Moderna COVID-19 vaccine), unknown route; 1 dosage form. On Jan 15, 2021, patient experienced lethargy (feeling lethargic), myalgia (achiness) and fatigue (mild to moderate fatigue). At the time of the report, lethargy (feeling lethargic), myalgia (achiness) and fatigue (mild to moderate fatigue): not resolved. The action taken with mRNA-1273 (Moderna COVID-19 vaccine): unknown. Concomitant medication not reported. Treatment details not reported by the reporter.
Mom reports child woke up with a fever of 105 degrees, vomited x 2.  Denies rash, cough, runny nose, conjunctivitis and diarrhea. Medicated with Motrin but vomited medication and breakfast.  Mother advise to take child to nearest UC or ER for evaluation. Nurse will follow up with mom tomorrow.
swelled; Very sore; This case was reported by a consumer via interactive digital media and described the occurrence of swelling in a patient who received Herpes zoster (Shingles vaccine) for prophylaxis.   On an unknown date, the patient received Shingles vaccine. On an unknown date, unknown after receiving Shingles vaccine, the patient experienced swelling and pain. On an unknown date, the outcome of the swelling and pain were recovered/resolved.   It was unknown if the reporter considered the swelling and pain to be related to Shingles vaccine.  Additional details were reported as follows: This case was reported by the patient for herself or himself. The age at vaccination was not reported. The patient had shingles vaccine and swelled 2 times and was very sore. Also stated that better than having shingles. No patient contact details were reported hence follow up not possible.
HEADACHE TO BACK OF HEAD, BEHIND THE RIGHT EAR; This spontaneous report received from a patient via a company representative concerned a 49 year old female. The patient's weight, height, and medical history were not reported. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: Unknown) dose was not reported, administered on 27-MAR-2021 for prophylactic vaccination. The batch number was not reported. The Company is unable to perform follow-up to request batch/lot numbers. No concomitant medications were reported.  On APR-2021, the subject experienced headache to back of head, behind the right ear. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient had not recovered from headache to back of head, behind the right ear. This report was non-serious.
This case was reported by a healthcare professional and described the occurrence of coldness in a 45-year-old female subject who was vaccinated with Flulaval (GlaxoSmithKline). Concurrent medical conditions included asthma. Concurrent vaccination included Pneumovax (Merck) given on 26 October 2007. Concurrent medications included Nasacort, Astelin, Zyrtec, Singulair, Fluoxetine, Oral contraceptive (OCP), Advair 100/50 1 puff daily and then increased to 1 puff twice daily, Qvar, M.V.I, Maxair and Robitussin. On 26 October 2007 the subject received unspecified dose of Flulaval at 0.5 ml in the left arm. On 28 October 2007, 2 days after vaccination with Flulaval, the subject experienced coldness, spasms, numbness and decreased motor strength in her hand. The subject experienced a systemic reaction. The healthcare professional considered the events were disabling. At the time of reporting the events of coldness, spasms, numbness and decreased motor strength in her hand were improved. The healthcare professional considered these events were probably related to vaccination with Flulaval.
Incident details: Per Drs. (Medical director) email sent out on 9/1/22-"the monovalent mRNA COVID-19 vaccines are not authorized as booster doses for individuals 12 years of age and older. Any patients that are currently scheduled to receive a booster should wait until we have the bivalent booster on hand." The patient was seen in office on 9/2/22 and received a booster dose of the monovalent mRNA COVID-19 vaccine (Pfizer) by RN in error as patients are now only supposed to receive the bivalent booster per Drs. email. Patient was due for booster at the time they received it, however the bivalent booster was not yet stocked. Possible Cause: Possible cause of the incident is that an email was sent out regarding the discontinuation of monovalent Covid boosters until Private receives the bivalent booster doses. This was overlooked by management and staff, as previous changes to clinic processes is usually discussed in a meeting. Also 'monovalent' and 'bivalent' are new terms that have not previously been used when discussing booster vaccines.  Corrective Action: Corrective action included notifying staff and providers of the recent change regarding COVID vaccines and were notified to stop giving COVID booster doses until the Clinic receives the bivalent vaccines. Staff and providers were notified via email, skype, and verbally. Incident reported to VAERS
(+) nodule to 1st anthrax. (+) erythema/edema to complete L arm post 2nd anthrax.
patient came in on 9/22 and stated she had pain in left arm where PPSV was given, "sharp pain, nerve pinching, redness, inflammation" - she has a scar on that arm from previous burn, she had about quarter-size bruising around the injection site - we think there is additional scar tissue under the skin that may have been it causing the pain. she is taking naproxen and will continue to take, counseled her to call MD if pain gets worse
Patient received Flulaval with no issue. Upon check-out of Clinic, patient began to appear red and complain that she couldn't breathe. RNs called to the front  at 1305 where the patient was sitting  in Waiting  Room. Brought to Exam Room, advised her to take her mask off and take some deep breaths. Dr. called into room who assessed patient. At this time, found out from Mom that patient had not eaten. Given juice and a lollipop, ice pack applied to neck. Pt able to breathe normal and feels much better with these measures.  1310 BP 112/73, HR 102. 1315 BP 101/63, HR 76. After resting 15 mins, cleared by Dr to be discharged. Follow up planned for tomorrow.
Chronic inflammation and pain. Premature atrial beats (heart attack) congestive, acute autoimmune reaction-ER admission. Anaphylaxis 7-8 yr. duration. Dyspnea (suffocation). Diffused (symptomatic of end stages of lupus). Diagnosed lupus (systemic) and Behcets-some sort of leukemia also yeast on tongue, burning.
High blood pressure; This spontaneous case was reported by a patient and describes the occurrence of HYPERTENSION (High blood pressure) in a 56-year-old female patient who received SPIKEVAX NOS (SPIKEVAX NOS) (batch no. A57165B) for COVID-19 prophylaxis.     The patient had no medical history, concomitant disease or risk factor.     On 13-Oct-2022, the patient received dose of SPIKEVAX NOS (SPIKEVAX NOS) (Intramuscular use) 1 dosage form. In October 2022, the patient experienced HYPERTENSION (High blood pressure). The patient was treated with AMLODIPINE for Blood pressure high, at a dose of 5 milligram. At the time of the report, HYPERTENSION (High blood pressure) had not resolved.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, Blood pressure measurement: The test prior to the booster was taken at home and was low normal. and Bp reflects a rise.  Blood pressure has remained high..     The action taken with SPIKEVAX NOS (SPIKEVAX NOS) (Intramuscular use) was unknown.       Concomitant medications were not reported.  It was reported that Bp was low normal prior to the booster. An increase was noted at the doctor office 2 weeks following booster.  Patient was now on high-blood-pressure medication.  It was unknown if the patient experienced any additional symptoms/events.   It is unknown if there were additional lab data/results available.
"I" have trouble with memory loss since "I" got the vaccine.; This is a spontaneous report from a contactable consumer, the patient. A 38-year-old non-pregnant female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: FC3181) via an unspecified route of administration in the left arm on 29Aug2021 at 11:00 (at the age of 38-years-old) as a single dose for COVID-19 immunisation. The patient had no relevant medical history. The patient had no known allergies. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient did not receive any other medications within two weeks of vaccination. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: FA7485) via an unspecified route of administration in the left arm on 08Aug2021 at 11:00 (at the age of 38-years-old) as a single dose for COVID-19 immunisation. On 30Aug2021 at 00:00, since got the vaccine, the patient had trouble with memory loss. Therapeutic measures were not taken as a result of the reported event. The adverse event did not result in doctor or other healthcare professional office/clinic visit and emergency room/department or urgent care. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event trouble with memory loss was not resolved at the time of this report.
Cluster of 3 cases out of an unspecified number of vaccines who received DECAVAC lot# U1923HA. Initial report received on 23 March 2007 from a healthcare professional. A 55 year old female patient, received on 02 March 2007 a dose of DECAVAC (lot# 01923HA), intramuscular into the left deltoid (needle size- 25 gauge). No other vaccines were given at that time. On 05 March 2007, 3 days post vaccination, the patient experienced tenderness in the left axillary region, redness and swelling was noted at the deltoid, extending to fingers below elbow. Pain continued on 14 March 2007. Treated with LEVOQUIN and  BENADRYL. The patient had not recovered. Medical history included fibromyalgia and penicillin allergy. Concomitant medications included NAPROXEN. The reporter denied illness and adverse event following prior vaccination. Dose and date of last Td vaccine were unknown. Unknown if other vaccines were given 4 weeks prior. Follow-up information received on 16 July 2007 from a health care professional. Per the reporter, the case was reviewed, and there was no additional information at this time. The reporter is the same as in cases 2007-00899 and 2007-00900.
My wife is unable to hear, she has a constant ringing, she has vertigo/dizziness, and nausea.  We discovered this after visiting an ENT on Monday, 4/19/21.  He said that my wife developed a viral infection in both of her ears, possibly due to the vaccination she received a week earlier.
Headache, fever between 101 in 103°, nausea, chills, vomiting, panting, shakes and chattering teeth. March 22 through March 31. I took Tylenol and ibuprofen.
Pt. receive vaccination at 14:10 PM. Patient was requested to remain on site 15 minutes for further observation as is our policy. Approximately five minutes later when patient was receiving her paperwork she looked at her mother and stated  ?I don?t feel good? . Patient then lost consciousness and was caught by her mother and the nurse, patient was then lowered to the ground. Once patient was on the ground, Patient was still unconscious and appear to have approximately 3 to 5 seconds of seizure like activity, patient was then turned onto her side to protect her airway. Approximately two seconds later she regained  consciousness and was completely lucid. Patient remained laying on the ground while nurse and EMT acquired vital signs. 02 saturation was 98% heart rate 98, blood pressure 110/74. Temperature was not taking its time. Patient did not complain of any dizziness or any other symptoms she stated that she felt OK and wanted to know what happened. Patient remained on the ground for approximately five more minutes and then was helped to a sitting position and reassessed at that point. Vitals continued to be stable and patient continue to be lucid. Patient was frequently reassessed throughout the event, and after approximately 10 minutes post event she was assisted to a chair and then back to her vehicle where she waited an additional 10 minutes to ensure that she continued to feel OK. Nurse instructed patient?s mother things to watch out for and also instructed patient to stay inside the rest of the day remain hydrated and avoid the heat. Also recommended to patient?s mother to follow up with primary care provider to inform them of the incident and also of the seizure like activity exhibited.
My lumbar spine has had 3 operations and 7 spinal injections. I feel the squalene agent that delivered the anthrax caused permanent damage to my spine.
Moderate to severe tinnitus in combination with serious fatigue , not constant, comes in waves , will last for hours No treatment
Superficial blood clot in right medial knee area. Aspirin, elevate right leg, compression and heat.
Pt states he experienced a rash starting "(about) two weeks after" he received the first Shingrix vaccine. The rash was present on his arms and upper torso. Per patient, Dr determined that it was clearly a reaction to the vaccine. The patient was told that he could use OTC Benadryl to treat the symptoms but states he declined to do so. He states that the rash has improved greatly since that time but has not entirely cleared as of today.
no adverse event; Improperly stored vaccines administered; This spontaneous report was received from other and refers to some patients. The patient's concurrent conditions, medical history and concomitant medications were not reported.  On 28-JUL-2023, the patient was vaccinated with hpv rl1 6 11 16 18 31 33 45 52 58 vlp vaccine (yeast) (GARDASIL 9) injection, 0.5 milliliter, three dose series, lot #W014513, expiration date: 26-JAN-2025, administered for prophylaxis (strength, and route of administration were not provided).  On 28-JUL-2023, 5 patients in total and additional patients were administered the affected hpv rl1 6 11 16 18 31 33 45 52 58 vlp vaccine (yeast) (GARDASIL 9) from the lot involved in a temperature excursion at the same location (Product storage error). No adverse events reported (No adverse event).  This is a non-valid case due to no patient's identifiers.  Follow up information has been received from an other health professional on 09-AUG-2023 and refers to a 12-year-old female patient. Concomitant medications included diphtheria vaccine toxoid (+) pertussis vaccine acellular (+) tetanus vaccine toxoid (TDAP) (lot # 213723, expiration date: 17-OCT-2025 via Right Deltoid) and meningococcal vaccine conj (lot # AMVA767A, expiration date: ??-DEC-2023 via Left Deltoid). The date of the patient was vaccinated with hpv rl1 6 11 16 18 31 33 45 52 58 vlp vaccine (yeast) (GARDASIL 9) was 04-AUG-2023 via Left Deltoid.  This is one of several reports from same reporter. ; Sender's Comments:  US-009507513-2309USA000747: US-009507513-2309USA000746: US-009507513-2309USA000745: US-009507513-2309USA000744: US-009507513-2309USA000743: US-009507513-2309USA000748:
This spontaneous report as received from a pharmacist refers to an unspecified number of patients of unknown ages and genders. On an unknown date, the patients were vaccinated with M-M-R II (dose, route and lot number were not reported), vaccine had been exposed to multiple excursions with highest temperature reaching 57F for total time of 206 hours and these vaccines' stability could not be supported. No adverse effects reported. This is one of several reports from the same source. Follow up information was received with patient identifiers. This case reported that M-M-R II (dose and route not reported, lot# J004201, therapy type unknown, expired date 12-APR-2015) was administered to a 4 year old patient. This is case 2 of 3 patients which were exposed to M-M-R II. This case was linked to cases: 1403USA006581 and 1404USA015675. Additional information has been requested.
Information has been received from a physician concerning a 71 year old male who on the afternoon of 6/13/05 was vaccinated with pneumococcal 23v polysaccharide vaccine (lot # 649914/0578P). The patient had previously been vaccinated with pneumococcal 23v polysaccharide vaccine about 5.5 years ago. On the evening of 6/13/05, the patient experienced pain in the injection arm, cellulitis from his triceps to his forearm. He had a fever of 100.5 F, aches, chills, headache and continuing arm pain. On 6/14/05, he was seen by his physician and was prescribed ibuprofen and dicloxacillin. On 6/16/05, the patient still had a swollen arm which was less painful and flu-like symptoms. The physician further indicated that as of 6/22/05, the patient was improving. The final diagnosis was cellulitis with fever, aches, chills, headache and pain being signs and symptoms. However, the physician reported that the reported flu-like symptoms were possibly not part of the cellulitis. The physician was unsure if the cellulitis or the flu-like symptoms were caused by the vaccination with pneumococcal 23v polysaccharide vaccine. It was confirmed that had the patient not been treated a more serious outcome could have occurred. There was no further information available. Additional information has been requested. (OMIC)